FAT jabs like Mounjaro and Wegovy could slash boozing by two-thirds, a study has shown.
It’s not the first time the medication has
Themimic the action of the natural GLP-1 hormone, which plays a key role in regulating blood sugar levels, appetite, and digestion.
They were initially developed to treat but have become a breakthrough in treatment, too.
Now, anecdotally, people have reported that
The study was led by Professor Carel le Roux, of University College Dublin and presented at this year’s European Congress on Obesity (ECO 2025).
Professor Le Roux said: “ have been shown treat obesity and reduce the risk of multiple obesity-related complications.
“Now, the beneficial effects beyond obesity, such as on intake, are being actively studied, with some promising results.”;
The team looked at data on the alcohol intake of patients who were being treated for obesity at a clinic in Dublin.
It involved 262 adults with a of over 27 with an average weight of 15st 6lb/98kg, and average age of 46 years.
They were prescribed either semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda) for weight loss. Mounjaro is the brand name for another medication, tirzepatide.
Thirty-one patients did not drink, 52 rarely drank, and 179 were regular drinkers, based on self reporting.
Some 188 of the 262 patients were followed-up for an average of four months. None of them had increased their alcohol intake.
Average alcohol intake decreased from 11.3 per week to 4.3 units per week after four months of treatment with the GLP-1 meds.
That’s the equivalent of drinking almost four large glasses of wine to one and a bit. Or, about six or seven pints of beer to roughly two.
Even more so, among the regular drinkers, intake decreased from 23.2 units per week to 7.8 units.
The reduction of 68 per cent is comparable to that achieved by nalmefene, a drug used to treat alcohol use disorder in Europe, notes Professor le Roux.
He adds: “The exact mechanism of how GLP-1 analogues reduce alcohol intake is still being investigated but it is thought to involve curbing cravings for alcohol that arise in subcortical areas of the brain that are not under conscious control.
“Thus, patients report the effects are ‘effortless’.”;
Alcohol use disorder is a relapsing condition that accounts for 2.6 million deaths a year – 4.7 per cent of all deaths globally.
Around one in 20 adults in England are deemed to be heavy drinkers – men who drink more than 50 units a week and women who drink more than 35 units.
. More than 8,200 people died because of alcohol in 2023 which is 42 per cent higher than in 2019.
Treatments such as cognitive behavioural therapy (CBT), therapies that aim to strengthen motivation to stop or reduce drinking and medication can be very successful in the short-term.
But 70 per cent of patients relapse within the first year, the study authors noted.
